Fundraising Fox
Petros Pharmaceuticals
OTC: PTPINew York, US · Founded 2020 · Delaware corporation · 1 known investors
Find your way into Petros Pharmaceuticals
Each arrow is one introduction. Sign up to fill in the first one.
137 people can intro you to Mitchell
Ask Jonathan Temlock to introduce you to Mitchell Arnold
You →Jonathan · together at RCN Corporation →Mitchell
120 people can intro you to Fady
Ask Jamie Chen to introduce you to Fady Boctor
You →Jamie · together at Hamline University →Fady
Sign up to find every way you can get introduced to Petros Pharmaceuticals
- Your email: who you already know at Petros Pharmaceuticals, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Petros Pharmaceuticals team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Petros Pharmaceuticals is a bio-pharmaceutical company working to convert prescription drugs into over-the-counter self-care treatments, allowing consumers access without a physician visit or prescription. It operates in the emerging self-care pharmaceutical market.
Founders & leadership
MA
Mitchell ArnoldVP, Finance and Chief Accounting OfficerMitchell Arnold is Vice President of Finance and Principal Accounting Officer at Petros Pharmaceuticals, a bio-pharmaceutical company developing over-the-counter alternatives to prescription drugs. He brings experience in financial leadership across public and private companies, including those backed by private equity and venture capital.
AG
Andrew GesekPresident, Timm Medical
FB
Fady BoctorPresident, Chief Commercial OfficerFady Boctor is a lifesciences executive with over 24 years of experience in corporate growth, portfolio management, sales force effectiveness, brand marketing, and market access, currently serving as President and Chief Commercial Officer at Petros Pharmaceuticals.
JD
WR
Wayne R. WalkerNamed on SEC filing
GB
Gregory BradleyNamed on SEC filing
JN
Joshua N. SilvermanNamed on SEC filing
BT
Bruce T. BernsteinNamed on SEC filing
Investors · 1
Juggernaut CapitalreportedWashington · $10M – $50M
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$35.7M disclosed across 3 of 4 rounds · 2021–2023
▶$30MraisedJul 2023 · 15 investors · PharmaceuticalsRule 506(b)
▶$30MraisedJul 2023 · 15 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John D. ShulmanDirector
- Mitchell ArnoldExecutive Officer
- Wayne R. WalkerDirector
- Fady BoctorExecutive Officer
- Gregory BradleyDirector
- Joshua N. SilvermanDirector
- Bruce T. BernsteinDirector
- Offering amount
- $30M
- Amount sold
- $30M
- Sales commissions
- $1.2M
- Placement agents
- Katalyst Securities LLC
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$2.2MraisedJan 2022 · 12 investors · PharmaceuticalsRule 506(b)
▶$2.2MraisedJan 2022 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Mitchell ArnoldExecutive Officer
- Gregory BradleyDirector
- Joshua N. SilvermanDirector
- Fady BoctorExecutive Officer
- John D. ShulmanDirector
- Andrew GesekExecutive Officer
- Bruce T. BernsteinDirector
- Wayne R. WalkerDirector
- Offering amount
- $8.3M
- Amount sold
- $2.2M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$3.5MraisedDec 2021 · 12 investors · PharmaceuticalsRule 506(b)
▶$3.5MraisedDec 2021 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Andrew GesekExecutive Officer
- Wayne R. WalkerDirector
- Mitchell ArnoldExecutive Officer
- Fady BoctorExecutive Officer
- Bruce T. BernsteinDirector
- John D. ShulmanDirector
- Gregory BradleyDirector
- Joshua N. SilvermanDirector
- Offering amount
- $12.8M
- Amount sold
- $3.5M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$5.9MofferedOct 2021 · 10 investors · PharmaceuticalsRule 506(b)
▶$5.9MofferedOct 2021 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John D. ShulmanDirector
- Wayne R. WalkerDirector
- Gregory BradleyDirector
- Mitchell ArnoldExecutive Officer
- Andrew GesekExecutive Officer
- Fady BoctorExecutive Officer
- Joshua N. SilvermanDirector
- Bruce T. BernsteinDirector
- Offering amount
- $5.9M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$12.3Mvaluation at IPOFeb 2025 · $0.24/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 7
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
PerplexityAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
ItigerTiger Brokers is a global online brokerage that lets clients trade equities, futures, options, and funds across U.S., Hong Kong, Singapore, and Australian markets through its Tiger Trade mobile app. Beyond brokerage, it offers ESOP management, investment banking, wealth management, and investor education, and is listed on NASDAQ under the ticker TIGR.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
TipRanksFinancial analysis and stock research platform.
Companies working in the same space as Petros Pharmaceuticals.
Frequently asked questions
- What does Petros Pharmaceuticals do?
- Petros Pharmaceuticals is a bio-pharmaceutical company working to convert prescription drugs into over-the-counter self-care treatments, allowing consumers access without a physician visit or prescription. It operates in the emerging self-care pharmaceutical market.
- Who are Petros Pharmaceuticals's investors?
- Petros Pharmaceuticals's investors include Juggernaut Capital.
- How much funding has Petros Pharmaceuticals raised?
- Petros Pharmaceuticals has disclosed $35.7M raised across 3 of its 4 known rounds.
- Where is Petros Pharmaceuticals headquartered?
- Petros Pharmaceuticals is headquartered in New York, US.